Oruka Therapeutics (NASDAQ:ORKA) Issues Earnings Results

Oruka Therapeutics (NASDAQ:ORKA) announced its earnings results on Wednesday. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.17, Zacks reports.

Oruka Therapeutics Stock Down 2.6%

Shares of ORKA stock opened at $9.46 on Friday. The firm has a market cap of $354.19 million, a price-to-earnings ratio of -1.51 and a beta of 0.25. The company’s 50 day moving average is $9.88 and its 200 day moving average is $15.01. Oruka Therapeutics has a 52-week low of $5.49 and a 52-week high of $31.13.

Analyst Ratings Changes

A number of brokerages have weighed in on ORKA. HC Wainwright reiterated a “buy” rating and set a $45.00 target price on shares of Oruka Therapeutics in a research note on Friday, February 7th. Wolfe Research initiated coverage on shares of Oruka Therapeutics in a report on Tuesday, February 4th. They set an “outperform” rating and a $20.00 price objective for the company. Finally, Wedbush reissued an “outperform” rating and set a $40.00 price objective on shares of Oruka Therapeutics in a report on Thursday. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $39.86.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.